Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.

PURPOSE: The vascular disrupting agent (VDA) combretastatin A4 phosphate (CA4P) induces significant tumor necrosis as a single agent. Preclinical models have shown that the addition of an anti-VEGF antibody to a VDA attenuates the revascularization of the surviving tumor rim and thus significantly i...

Full description

Bibliographic Details
Main Authors:	Nathan, P, Zweifel, M, Padhani, A, Koh, D, Ng, M, Collins, D, Harris, A, Carden, C, Smythe, J, Fisher, N, Taylor, N, Stirling, J, Lu, S, Leach, M, Rustin, G, Judson, I
Format:	Journal article
Language:	English
Published:	2012

Similar Items

A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
by: Nathan, P, et al.
Published: (2008)

A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors
by: Nathan, P, et al.
Published: (2007)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
by: Rustin, G, et al.
Published: (2010)

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results
by: Zweifel, M, et al.
Published: (2009)

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
by: Zweifel, M, et al.
Published: (2011)

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.
by: Rustin, G, et al.
Published: (2003)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
by: Lunt, S, et al.
Published: (2011)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate
by: Jane Lunt, S, et al.
Published: (2011)

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
by: Meyer, T, et al.
Published: (2009)

The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.
by: Brooks, A, et al.
Published: (2003)

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
by: Tozer, G, et al.
Published: (2001)

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
by: Galbraith, S, et al.
Published: (2001)

The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.
by: Prise, V, et al.
Published: (2002)

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.
by: Thomson, P, et al.
Published: (2006)

Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.
by: Tozer, G, et al.
Published: (2009)

Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI.
by: Maxwell, R, et al.
Published: (2002)

Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles.
by: Mehta, S, et al.
Published: (2011)

Biomarkers to predict the clinical efficacy of bevacizumab in cancer.
by: Jubb, A, et al.
Published: (2010)

Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection.
by: Stratford, MR, et al.
Published: (2012)

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection
by: Stratford, M, et al.
Published: (2011)

Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab.
by: Koukourakis, M, et al.
Published: (2009)

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection.
by: Stratford, MR, et al.
Published: (2011)

Bevacizumab--current status and future directions.
by: Midgley, R, et al.
Published: (2005)

Bevacizumab and type 1 idiopathic macular telangiectasia
by: Koay, C.L., et al.
Published: (2011)

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer.
by: Jubb, A, et al.
Published: (2011)

Enhanced fluorescence detection of cis-combretastatins by post-column photolysis.
by: Stratford, MR
Published: (2008)

Development of bevacizumab-conjugated ferromagnetic nanoparticles for non-invasive angiogenesis detection
by: Bouziotis, P, et al.
Published: (2009)

Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion
by: Rush, R, et al.
Published: (2014)

Optimization of superconducting properties of the stoichiometric CaKFe4As4
by: Singh, S, et al.
Published: (2019)

Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using (111)In-bevacizumab.
by: Patel, N, et al.
Published: (2017)

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts
by: Kumar, K, et al.
Published: (2013)

Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.
by: Kumar, K, et al.
Published: (2013)

Pleural diseases: saline irrigation in pleural infection, epidemiology of pneumothorax, and bevacizumab in mesothelioma
by: Corcoran, J, et al.
Published: (2017)

PERBEDAAN KEKUATAN KOMPRESI SEMEN ALPHA TRICALCIUM PHOSPHATE (Î±-TCP) DENGAN PENGGUNAAN LARUTAN DISODIUM HYDROGEN PHOSPHATE (Na2HPO4) DAN SODIUM DIHYDROGEN PHOSPHATE (NaH2PO4)
by: , PRIZTIKA WIDYA N, et al.
Published: (2013)

Investigation of differentially expressed genes that contribute to therapeutic effects of bevacizumab in BRAF mutant melanoma
by: Coupe, N
Published: (2020)

Luminescence of CaWO4, CaMoO4, and ZnWO4 scintillating crystals under different excitations
by: Mikhailik, V, et al.
Published: (2005)

Bevacizumab promotes T-cell–mediated collagen deposition in the mouse model of conjunctival scarring
by: Seet, Li-Fong, et al.
Published: (2019)

Optimization of superconducting properties of the stoichiometric CaKFe4As4
by: Coldea, A, et al.
Published: (2019)

Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
by: Chakravarthy, U, et al.
Published: (2012)

Persistence of antiferromagnetic order upon La substitution in the 4d4 Mott insulator Ca2RuO4
by: Boothroyd, A, et al.
Published: (2018)